Clinical Trials Logo

NSCLC Stage IIIB clinical trials

View clinical trials related to NSCLC Stage IIIB.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05212922 Withdrawn - HCC Clinical Trials

A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC

YH001
Start date: June 2023
Phase: Phase 2
Study type: Interventional

This is an Open-label, Non-Randomized, Multi-center Phase 2 study of YH001 in Combination with Toripalimab,The study is designed to determine the safety ,tolerability and antitumor activity of YH001 in combination with Toripalimab in subjects with advanced NSCLC and HCC.

NCT ID: NCT03628144 Withdrawn - Clinical trials for Non-small Cell Lung Cancer

Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer

Start date: July 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess whether either or both nutrition supplements (Impact® Advanced Recovery or Boost® High Protein) ingested prior to and during concurrent chemoradiotherapy decreases toxic side effects of treatment in Stage IIIA-B non-small cell lung cancer.

NCT ID: NCT03231475 Withdrawn - NSCLC Stage IV Clinical Trials

Phase I Study of SPH1188-11 in NSCLC

SPH1188-11
Start date: July 21, 2017
Phase: Phase 1
Study type: Interventional

This study will treat patients with advanced NSCLC who have already received at least one course of specific anti-cancer treatment but the tumour has started to re-grow following that treatment. This is the first time this drug has ever been tested in patients, and so it will help to understand what type of side effects may occur with the drug treatment, it will measure the levels of drug in the body, it will also measure the anti-cancer activity. By using these pieces of information together the best dose of this drug to use in further clinical trials will be selected.